CordenPharma is pleased to announce that CordenPharma Latina, located near Sermoneta, Italy, has received news that the US-FDA warning letter previously received has been closed, with a closeout date of 15 August 2017.
This success is the result of a holistic and systematic approach to remediate the observations throughout the facility.
Since inception, CordenPharma’s Corporate Compliance Team has developed a company wide strategic approach to enhancing all quality and compliance systems by systematically reviewing and assessing each CordenPharma facility and establishing harmonisation programmes, knowledge management and sharing of best practices.
To ensure effectiveness, CordenPharma has planned a long-term high investment programme in regards to corporate and quality systems, organisational structure and infrastructure, including a process to involve customers in improving transparency.
CordenPharma’s Leadership Team is committed to enabling all facilities to operate according to the highest level of quality, compliance structures and systems, with a consistent focus on patient safety, guidelines, legislations and strict adherence to current industry standards.
CordenPharma is currently achieving and sustaining these quality and compliance objectives proactively through continuous improvement strategies and collaboration with regulatory agencies, with the aim to serve patients and customers worldwide as a reliable and benchmark CDMO partner in the pharmaceutical, biotech and healthcare industry.